{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:24:27Z","timestamp":1761744267605},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40264-016-0394-0","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T15:43:29Z","timestamp":1455119009000},"page":"409-419","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety Profile of Atorvastatin 80\u00a0mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants"],"prefix":"10.1007","volume":"39","author":[{"given":"Haixia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cailian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"issue":"4","key":"394_CR1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","volume":"5","author":"C Stancu","year":"2001","unstructured":"Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378\u201387.","journal-title":"J Cell Mol Med."},{"issue":"Suppl 1","key":"394_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/1153644-S0-000000000-00000","volume":"10","author":"M Marzilli","year":"2010","unstructured":"Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(Suppl 1):3\u20139.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"Suppl 1","key":"394_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003495-200767001-00004","volume":"67","author":"M Arca","year":"2007","unstructured":"Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs. 2007;67(Suppl 1):29\u201342.","journal-title":"Drugs."},{"issue":"6","key":"394_CR4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1517\/14656566.6.6.915","volume":"6","author":"KK Ray","year":"2005","unstructured":"Ray KK, Cannon CP. Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother. 2005;6(6):915\u201327.","journal-title":"Expert Opin Pharmacother."},{"issue":"14","key":"394_CR5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"325","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;325(14):1425\u201335.","journal-title":"N Engl J Med."},{"issue":"6","key":"394_CR6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u201359.","journal-title":"N Engl J Med."},{"issue":"3","key":"394_CR7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","volume":"48","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438\u201345.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"394_CR8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/hrt.2006.112508","volume":"93","author":"J Afilalo","year":"2007","unstructured":"Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart. 2007;93(8):914\u201321.","journal-title":"Heart."},{"issue":"6","key":"394_CR9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","volume":"92","author":"CB Newman","year":"2003","unstructured":"Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92(6):670\u20136.","journal-title":"Am J Cardiol."},{"issue":"2","key":"394_CR10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","volume":"95","author":"S Wissen van","year":"2005","unstructured":"van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol. 2005;95(2):264\u20136.","journal-title":"Am J Cardiol."},{"issue":"1","key":"394_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9150(99)00294-4","volume":"149","author":"RG Bakker-Arkema","year":"2000","unstructured":"Bakker-Arkema RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis. 2000;149(1):123\u20139.","journal-title":"Atherosclerosis."},{"issue":"4","key":"394_CR12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.2010.495385","volume":"9","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf. 2010;9(4):667\u201374.","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"394_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","volume":"97","author":"C Newman","year":"2006","unstructured":"Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80\u00a0mg versus 10\u00a0mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97(1):61\u20137.","journal-title":"Am J Cardiol."},{"key":"394_CR14","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ."},{"key":"394_CR15","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. http:\/\/www.cochrane-handbook.org . Accessed 2 Aug 2015."},{"issue":"4","key":"394_CR16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"394_CR17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.hrthm.2011.09.016","volume":"9","author":"M Suleiman","year":"2012","unstructured":"Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. Heart Rhythm. 2012;9(2):172\u20138.","journal-title":"Heart Rhythm."},{"issue":"12","key":"394_CR18","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1210\/jc.2006-1909","volume":"92","author":"HG Bone","year":"2007","unstructured":"Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab. 2007;92(12):4671\u20137.","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"394_CR19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.clinthera.2008.12.023","volume":"30","author":"J Bonnet","year":"2008","unstructured":"Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, et al. Comparative effects of l0-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic Effects) study. Clin Ther. 2008;30(12):2298\u2013313.","journal-title":"Clin Ther."},{"issue":"6","key":"394_CR20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1185\/03007991003751496","volume":"26","author":"F Colivicchi","year":"2010","unstructured":"Colivicchi F, Tubaro M, Mocini D, Genovesi Ebert A, Strano S, Melina G, et al. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Curr Med Res Opin. 2010;26(6):1277\u201384.","journal-title":"Curr Med Res Opin."},{"issue":"10","key":"394_CR21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","volume":"62","author":"A Tawakol","year":"2013","unstructured":"Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation. J Am Coll Cardiol. 2013;62(10):909\u201317.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"394_CR22","first-page":"97","volume":"61","author":"U Kaul","year":"2013","unstructured":"Kaul U, Varma J, Kahali D, Hiremath MS, Dani S, Dalal J, et al. Post-marketing study of clinical experience of atorvastatin 80\u00a0mg vs 40\u00a0mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS). J Assoc Physicians India. 2013;61(2):97\u2013101.","journal-title":"J Assoc Physicians India."},{"issue":"19","key":"394_CR23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319.","journal-title":"N Engl J Med."},{"issue":"10","key":"394_CR24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/00044011-200828100-00003","volume":"28","author":"PH Jones","year":"2008","unstructured":"Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625\u201334.","journal-title":"Clin Drug Investig."},{"issue":"6","key":"394_CR25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(01)02337-2","volume":"89","author":"DG Karalis","year":"2002","unstructured":"Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 2002;89(6):667\u201371.","journal-title":"Am J Cardiol."},{"issue":"13","key":"394_CR26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138.","journal-title":"JAMA."},{"issue":"1","key":"394_CR27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ahj.2004.07.025","volume":"149","author":"PH Jones","year":"2005","unstructured":"Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005;149(1):e1.","journal-title":"Am Heart J."},{"issue":"3","key":"394_CR28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.105.568147","volume":"113","author":"A Schmermund","year":"2006","unstructured":"Schmermund A, Achenbach S, Budde T, Buziashvili Y, F\u00f6rster A, Friedrich G, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months:\u00a0a multicenter, randomized, double-blind trial. Circulation. 2006;113(3):427\u201337.","journal-title":"Circulation."},{"issue":"1","key":"394_CR29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96\u2013103.","journal-title":"Circulation."},{"issue":"8","key":"394_CR30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/hrt.2006.102848","volume":"93","author":"CM Yu","year":"2007","unstructured":"Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart. 2007;93(8):933\u20139.","journal-title":"Heart."},{"issue":"5\u20136","key":"394_CR31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1440-1681.2008.05110.x","volume":"36","author":"Z Zhao","year":"2009","unstructured":"Zhao Z, Geng J, Ge ZM, Wang W, Zhang Y, Kang WQ. Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina. Clin Exp Pharmacol Physiol. 2009;36(5\u20136):554\u20138.","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"9","key":"394_CR32","first-page":"1772","volume":"44","author":"MJ Koren","year":"2004","unstructured":"Koren MJ, Hunninghake DB. ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary hear disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772\u20139.","journal-title":"J Am Coll Cardiol."},{"issue":"9","key":"394_CR33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071\u201380.","journal-title":"JAMA."},{"issue":"9601","key":"394_CR34","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","volume":"370","author":"J Armitage","year":"2007","unstructured":"Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781\u201390.","journal-title":"Lancet."},{"issue":"5A","key":"394_CR35","doi-asserted-by":"crossref","first-page":"69F","DOI":"10.1016\/j.amjcard.2005.06.028","volume":"96","author":"DD Water","year":"2005","unstructured":"Water DD. Safety of high-dose atorvastatin therapy. Am J Cardiol. 2005;96(5A):69F\u201375F.","journal-title":"Am J Cardiol."},{"issue":"2","key":"394_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcr158","volume":"105","author":"M Alberton","year":"2012","unstructured":"Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect\u00a0comparison meta-analysis. QJM. 2012;105(2):145\u201357.","journal-title":"QJM."},{"issue":"4","key":"394_CR37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246955 participants from 135 randomized, controlled\u00a0trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0394-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-016-0394-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0394-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:38Z","timestamp":1559504498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-016-0394-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s40264-016-0394-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]}}}